 BOSTON and LOUISVILLE Ky., Sept. 06, 2022 GLOBE NEWSWIRE -- Talaris Therapeutics, Inc. Nasdaq: TALS, a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences: 